Eton, Omar E., MD, FACP
Hartford HealthCare Medical Group

Omar E. Eton, MD, FACP

Medical Oncology

Location Information

  • Hartford HealthCare Cancer Institute at Hartford Hospital
    85 Seymour Street Suite 125
    Hartford, CT 06106

    860.676.7000

    Fax: 860.676.7005

About Omar E. Eton, MD, FACP

  • Gender
    Male
  • Languages
    English
    French
    Spanish
    Providing the best care to our patients and their companions requires communicating in a way everyone understands. Interpreter services are available 24 hours a day, 7 days a week, 365 days a year. All spoken languages are available, as well as American Sign Language (AS/L)
  • Specialties
    Accepting New Patients

    Medical Oncology

    Not Currently Accepting New Patients

    Internal Medicine

  • Areas of Expertise
    Immunotherapy, Melanoma, Phase 1 Clinical Trials, Signal Transduction, Skin Cancer, Translational Research

Education

  • FellowshipMemorial Sloan Kettering Cancer Center

    Medical SchoolNew York University School of Medicine

    ResidencyParkland Memorial Hospital, The University of Texas Southwestern

    UndergraduateHarvard College

  • Professional Organizations

    American Society of Hematology
    American Association of Cancer Research
    Society for Melanoma Research
    American Association for the Advancement of Science
    New York Academy of Science
    American College of Physicians
    American Medical Association
    Society of United States Air Force Flight Surgeons
    Association of Military Surgeons of the United States
    Texas Medical Association

Reviews

Other Reviews from Around the Web

Bio

Omar Eton, MD, an expert with IL2 and cytokine-release syndrome management, arrived at Hartford HealthCare in 2017 as the Cancer Institute’s first medical director of melanoma and skin cancer, overseeing phase 1 trials and the immunotherapy program. He came with a rich work history in the field, starting with an immunology/oncology/hematology fellowship at Memorial Sloan Kettering (MSK) Cancer Center working with the team now leading MSK melanoma efforts. He is most known for “separating apples from oranges” in stage 4 disease prognostic subgroups, developing biochemotherapy, and running the first National Cancer Institute trial in melanoma – with the first response - for Gleevec, ultimately leading to its Food & Drug Administration approval for kit-mutated disease. During this time, he was a reservist with the US Air Force Medical Corps and was recalled for a year after 9/11. He then directed the phase 1 development of an aurora A kinase inhibitor for Millennium Pharmaceuticals in Cambridge, MA, and joined a colleague at Boston University Medical Center, seeing patients with a broad array of oncology and hematology problems for seven years. He enjoys kayaking on the Charles River, hiking the Presidential range in NH, biking, and playing backgammon.

Media

Insurance

Aetna, Anthem, BCBS Medicare, CarePartners of Connecticut, Cigna Healthcare, Colonial Cooperative Care, Community Health Network of Connecticut, Inc., Connecticare, Connecticare Commercial, Connecticare Medicare, Corvel, Coventry, Essence Healthcare, Evercare, First Health Group Corp., Focus, Harvard Pilgrim, Health Connecticut, Health Direct, Health New England, Healthy Connecticut, HMC/ Northeast Healthcare, Multiplan, Northeast Health Direct, One Health Plan/ Great-West Healthcare, Oxford Health Plans, Prime Health Services, Private Health Care Systems, Inc., Senior Whole Health, United Healthcare, WellCare of Connecticut, Inc.
This information is subject to change at any time. Please check with your insurance provider before scheduling your appointment or receiving services to confirm they are a participating member of the Hartford HealthCare network.
Back to Top